{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-249692","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2026-06-01T11:00:19+00:00","discovered_at":"2026-06-01T11:05:00.291444+00:00","generated_at":"2026-06-01T11:06:39.408014+00:00","sec_items":["3.02","3.03","5.03","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors","bullets":["Board approved 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.","Stockholders holding 57.1% of shares approved via written consent on April 28, 2026.","Appointed Stephen W. Webster (former CFO of Spark Therapeutics) and Nina Kjellson (Canaan Partners GP) to Board.","Board reduced from six to five directors; each new director received an option to purchase 13,587 shares.","Common stock trading on OTC Pink under symbol ELOX will begin split-adjusted on June 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249692","json":"https://secwatch.observer/filing/0001193125-26-249692.json","markdown":"https://secwatch.observer/filing/0001193125-26-249692.md","text":"https://secwatch.observer/filing/0001193125-26-249692.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/d261568d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T11:06:39.408014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14d4f6818a","claim":"Stephen W. Webster was appointed as Director at Eloxx Pharmaceuticals, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","confidence":0.95},{"claim_id":"b89010160f","claim":"Nina Kjellson was appointed as Director at Eloxx Pharmaceuticals, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001104659-26-068521","ticker":"FDXF","company_name":"FedEx Freight Holding Company, Inc.","filed_at":"2026-06-01T10:46:03+00:00","headline":"FedEx Freight completes spin-off from FedEx; $600M drawn, new board and executives appointed","event_type":"other_material","sec_items":["1.01","2.03","3.03","5.03","5.01","5.02","5.05","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 3.03, 5.02, 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068521","json":"https://secwatch.observer/filing/0001104659-26-068521.json","markdown":"https://secwatch.observer/filing/0001104659-26-068521.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/tm2615735d2_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","comparable_excerpt":"each of John A. Smith, R. Brad Martin, Jeffrey A. Davis, Donald E. Frieson, Stephen E. Gorman, Robert A. King, Cindy J. Miller, Amy J. Salcido, and Samantha M. Smith was appointed to the Board","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm"}},{"accession":"0001829126-26-005831","ticker":"FXAC","company_name":"FortuneX Acquisition Corp","filed_at":"2026-05-29T21:32:49+00:00","headline":"FortuneX Acquisition closes IPO of 8.625M units at $10/unit, raising $86.25M gross","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: executive_change","same SEC item: 3.02, 5.02, 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-005831","json":"https://secwatch.observer/filing/0001829126-26-005831.json","markdown":"https://secwatch.observer/filing/0001829126-26-005831.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2121703/000182912626005831/0001829126-26-005831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2121703/000182912626005831/fortunexacq_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","comparable_excerpt":"Effective May 19, 2026, in connection with the effectiveness of the Company’s Registration Statement, Becky Fallon, Sean Michael Deegan, and Robert Labbe became members of the board of directors (the “Board”) of the Company.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2121703/000182912626005831/0001829126-26-005831-index.htm"}},{"accession":"0001213900-26-061493","ticker":"OHAC","company_name":"Oceanhawk Acquisition Corp.","filed_at":"2026-05-27T20:01:23+00:00","headline":"Oceanhawk Acquisition Corp. closes upsized $160M IPO of 16M units at $10/unit","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 3.02, 5.02, 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061493","json":"https://secwatch.observer/filing/0001213900-26-061493.json","markdown":"https://secwatch.observer/filing/0001213900-26-061493.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2090787/000121390026061493/0001213900-26-061493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2090787/000121390026061493/ea0292099-8k_oceanhawk.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","comparable_excerpt":"On May 20, 2026, in connection with the IPO, each of Joseph Durnford, Ernest Miller, Jon Ryan, Mike Maggard, Dan Collingridge-Padbury and Jonathan Nickell (collectively, the “ Directors ”) was appointed to the board of directors of the Company (the “ Board ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2090787/000121390026061493/0001213900-26-061493-index.htm"}},{"accession":"0001493152-26-026544","ticker":"LIXT","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2026-06-01T12:55:34+00:00","headline":"Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board","event_type":"other_material","sec_items":["5.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026544","json":"https://secwatch.observer/filing/0001493152-26-026544.json","markdown":"https://secwatch.observer/filing/0001493152-26-026544.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/form8-k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","comparable_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm"}},{"accession":"0001171843-26-003809","ticker":"CRMT","company_name":"AMERICAS CARMART INC","filed_at":"2026-05-29T21:30:17+00:00","headline":"America's Car-Mart forms special committee for strategic alternatives; appoints new independent director","event_type":"other_material","sec_items":["1.01","5.02","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003809","json":"https://secwatch.observer/filing/0001171843-26-003809.json","markdown":"https://secwatch.observer/filing/0001171843-26-003809.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/799850/000117184326003809/0001171843-26-003809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/799850/000117184326003809/f8k_052926.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","comparable_excerpt":"On May 22, 2026, the Board increased the size of the Board from nine members to ten members and appointed Adam Paul as an independent director, effective immediately.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/799850/000117184326003809/0001171843-26-003809-index.htm"}},{"accession":"0000947871-26-000585","ticker":"MVST","company_name":"Microvast Holdings, Inc.","filed_at":"2026-05-28T21:26:49+00:00","headline":"Microvast CEO converts $25M loan to equity; CAO Eric Garcia departs","event_type":"other_material","sec_items":["5.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000947871-26-000585","json":"https://secwatch.observer/filing/0000947871-26-000585.json","markdown":"https://secwatch.observer/filing/0000947871-26-000585.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760689/000094787126000585/0000947871-26-000585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760689/000094787126000585/ss6384648_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","comparable_excerpt":"On May 27, 2026, Eric N. Garcia ceased to be employed as Chief Accounting Officer of Microvast Holdings, Inc. (the “Company”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1760689/000094787126000585/0000947871-26-000585-index.htm"}},{"accession":"0001636282-26-000056","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-05-29T20:45:58+00:00","headline":"Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-26-000056","json":"https://secwatch.observer/filing/0001636282-26-000056.json","markdown":"https://secwatch.observer/filing/0001636282-26-000056.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/0001636282-26-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/syre-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","comparable_excerpt":"In addition, effective as of May 27, 2026, Peter Harwin resigned from the Board.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/0001636282-26-000056-index.htm"}},{"accession":"0001628280-26-038821","ticker":"ENS","company_name":"EnerSys","filed_at":"2026-05-28T20:15:50+00:00","headline":"EnerSys realigns to three segments, names presidents for NIS, IMS, PPS","event_type":"other_material","sec_items":["5.02","7.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-038821","json":"https://secwatch.observer/filing/0001628280-26-038821.json","markdown":"https://secwatch.observer/filing/0001628280-26-038821.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1289308/000162828026038821/0001628280-26-038821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1289308/000162828026038821/ens-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","comparable_excerpt":"As a result of the Company's Segment Realignment there will be a change in executive titles as follows: • Keith D. Fisher – President, Network & Infrastructure Solutions • Chad C. Uplinger – President, Industrial Mobility Solutions • Mark E. Matthews – Chief Technology Officer and President, Precision Power Solutions","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1289308/000162828026038821/0001628280-26-038821-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}